Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc reports on the outcomes of the Annual General Meeting (AGM) held on May 12, 2022. The filing serves as a notification of corporate governance actions and shareholder resolutions rather than a financial performance report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on voting results for corporate resolutions.
Material Changes and Voting Results
All resolutions proposed at the AGM were passed. Key voting outcomes include:
- Accounts Approval: The 2021 annual accounts were adopted with 100% of votes cast in favor.
- Remuneration Report: Approved with 99.34% support.
- Remuneration Policy: Approved with 80.97% support, with 19.03% voting against.
- Director Re-elections: Travis Coy, Professor Sir Peter J. Ratcliffe, and Roy S. Herbst were re-elected with support ranging from 85.50% to 85.80%.
- Auditor Appointment: KPMG LLP was re-appointed with 100% support.
- Share Repurchase Authority: Shareholders authorized the repurchase of deferred shares with 99.98% support.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, financial outlook, operational risks, or contingencies. It strictly documents the procedural completion of the AGM agenda.
Investor Verification Checklist
- Verify the full text of the Notice of Annual General Meeting on the company website for detailed resolution descriptions.
- Review the 2021 UK Annual Report for the financial data referenced in Resolution 1.
- Confirm the implementation timeline for the new Directors' Remuneration Policy effective immediately post-AGM.
- Monitor future filings for the execution of the authorized share repurchase contract.